{Reference Type}: Systematic Review
{Title}: Merkel cell carcinoma associated with TNF inhibitor therapy: a systematic review of case reports.
{Author}: Almashali M;Alotaibi MA;Shadid A;
{Journal}: Dermatol Online J
{Volume}: 30
{Issue}: 2
{Year}: 2024 Apr 15
暂无{DOI}: 10.5070/D330263575
{Abstract}: A rare neuroendocrine skin cancer called Merkel cell carcinoma (MCC) primarily affects elderly people. The objective of this study is to comprehensively review the impact of immunosuppressive medications, particularly TNF inhibitors, on the emergence of MCC.<BR><B>METHODS: </B>PubMed, Web of Science, Science Direct, and Cochrane Library were searched. Study articles were screened by title and abstract at Rayyan Qatar Computing Research Institute, then a full-text assessment was implemented.<BR><B>RESULTS: </B>A total of eight case reports with 9 patients were included. Of the total population, seven were women and only two were men. Their age ranged from 31 to 73 years. More than half the population (5 cases) were being treated for rheumatoid arthritis. All received TNF inhibitors that were associated with the induction of MCC.<BR><B>CONCLUSIONS: </B>We found that it is essential for physicians to explain potential cancer risks to patients before starting long-term immunosuppressive therapy and to conduct routine checks for MCC and other side effects. TNF inhibitors (infliximab, adalimumab, etanercept, and golimumab) were all associated with MCC development. Women constituted the majority of cases and most were elderly.